Asmacure appoints Martin Driscoll CEO
This article was originally published in Scrip
Executive Summary
Asmacure, a clinical-stage biopharma company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, has appointed Martin Driscoll chief executive officer. Mr Driscoll was previously CEO and a director of Javelin Pharmaceuticals and will succeed Dr Luc Vachon, who is leaving the company to pursue other business ventures.